

## Match Overview

1	<b>Internet</b> 77 words crawled on 12-Jan-2014 <a href="http://www.plosone.org">www.plosone.org</a>	3%
2	<b>CrossCheck</b> 33 words Adán, Alfredo, Laura Pelegrín, Amanda Rey, Víctor Llorenç, Marina Mesquida, Blanca Molins, José Ríos, and Johann	1%
3	<b>Internet</b> 29 words crawled on 16-Oct-2011 <a href="http://lasereyesurgery.researchtoday.net">lasereyesurgery.researchtoday.net</a>	1%
4	<b>Internet</b> 26 words crawled on 15-Dec-2011 <a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a>	1%
5	<b>Internet</b> 24 words crawled on 25-Feb-2014 <a href="http://revophth.com">revophth.com</a>	1%
6	<b>Internet</b> 21 words crawled on 05-Jun-2013 <a href="http://www.abstractboard.com">www.abstractboard.com</a>	1%
7	<b>Internet</b> 21 words crawled on 06-Oct-2012	1%

Name of journal: World Journal of Ophthalmology

ESPS Manuscript NO: 16150

Columns: Editorial

Approved pharmacotherapy<sup>15</sup> for macular edema secondary to branch retinal vein occlusion: A review of randomized controlled trials in dexamethasone implants, ranibizumab, and aflibercept

Jia-Kang Wang

#### Abstract

There are three approved pharmacotherapies for<sup>8</sup> treating macular edema secondary to branch retinal vein occlusion (BRVO), including corticosteroids (dexamethasone implants) and<sup>10</sup> anti-vascular endothelial growth factor (VEGF) (ranibizumab and aflibercept). They all show superior ability to improve vision and reduce macular thickness, comparing with sham injections or macular grid laser treatment. There is no severe ocular or systemic adverse reaction reported in studies associated with anti-VEGF for macular edema after BRVO. Intraocular pressure elevation and cataract aggravation should be addressed after intravitreal dexamethasone implants. Single intravitreal dexamethasone implant had effective duration as long as four to six months. Intravitreal anti-VEGF requires six monthly injections as loading doses, and then PRN regimen needed according to functional and anatomical changes. Ozurdex and ranibizumab

[网页](#)[图片](#)[新闻](#)[视频](#)[更多 ▾](#)[搜索工具](#)

找到约 33,200 条结果 (用时 0.85 秒)

## Google 学术: Approved pharmacotherapy for macular edema secondary to branch retinal vein occlusion

... edema secondary to branch retinal vein occlusion - Rabena - 被引用次数: 250

... edema secondary to branch retinal vein occlusion - Cekic - 被引用次数: 150

... edema secondary to branch retinal vein occlusion: ... - Wu - 被引用次数: 103

### Therapeutic potential of intravitreal pharmacotherapy in ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > ... > PubMed Central (PMC) ▾ [翻译此页](#)

作者: ML Shahsuvaryan - 2012 - 被引用次数: 10 - 相关文章

2012年12月18日 - Retinal vein occlusion (RVO) is the most common visually disabling ... retinal vein occlusion (CRVO) and branch retinal vein occlusion ..... Ranibizumab has first received FDA approval for the treatment of macular edema due ...

### Regeneron Announces EYLEA® (aflibercept) Injection ...

[investor.regeneron.com/releaseDetail.cfm?ReleaseID=883500](http://investor.regeneron.com/releaseDetail.cfm?ReleaseID=883500) ▾ [翻译此页](#)

2014年11月18日 - EYLEA has already been approved in Japan for the treatment of ... of macular edema secondary to branch retinal vein occlusion (BRVO).

### Combination Therapy for Macular Edema Secondary to ...

[www.healio.com/.../combination-therapy-for-macular-edema-s...](http://www.healio.com/.../combination-therapy-for-macular-edema-s...) ▾ [翻译此页](#)

作者: EW Schneider - 2013 - 被引用次数: 2 - 相关文章



[网页](#)[新闻](#)[图片](#)[视频](#)[更多 ▾](#)[搜索工具](#)

找到约 2,490 条结果 (用时 0.82 秒)

### Therapeutic potential of intravitreal pharmacotherapy in ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > ... > [PubMed Central \(PMC\)](#) ▾ [翻译此页](#)

作者: ML Shahsuvaryan - 2012 - 被引用次数: 11 - 相关文章

2012年12月18日 - **Retinal vein occlusion** (RVO) is the most common visually disabling disease ... (FDA) **approval** of the **dexamethasone** intravitreal **implant** (Ozurdex, ... The rationale for using steroids to treat **macular edema secondary** to RVO is ... study, was consisted of 2 multicentere **randomized, controlled clinical trials** ...

### Efficacy and Safety of Intravitreal Therapy in Macular Edema ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > ... > [Literature](#) > [PubMed Central \(PMC\)](#) - [翻译此页](#)

作者: A Pielen - 2013 - 被引用次数: 26 - 相关文章

2013年10月25日 - 11 **RCTs** investigating anti-VEGF agents (**ranibizumab**, bevacizumab, ... The effect of **dexamethasone implant** was transient after 1.9 implants in both indications. .... dexamethasone, **ranibizumab**, bevacizumab or **aflibercept** in **macular edema due to** .... Bar graph for results in **branch retinal vein occlusion**.

缺少字词: pharmacotherapy

### Retina Today - Treatments for Retinal Vein Occlusion: A ...

[retinatoday.com/2014/04/treatments-for-retinal-vein-occlusion](http://retinatoday.com/2014/04/treatments-for-retinal-vein-occlusion) ▾ [翻译此页](#)

**Retinal vein occlusions** (RVOs), including both **branch** and central veins, are the ... Two of these (**dexamethasone** intravitreal **implant** and **ranibizumab**) are also FDA **approved** for the treatment of **macular edema secondary** to BRVO. .... The phase 3 VIBRANT trial<sup>22</sup> was a double masked, randomized, active controlled study.